Company Encyclopedia
View More
name
Black Diamond Therapeutics
BDTX.US
Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company’s lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as Phase 1 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in Phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage.
1.946 T
BDTX.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
B
BiotechnologyIndustry
Industry Ranking44/393
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE19.23%A
    • Profit Margin30.71%A
    • Gross Margin0.00%E
  • Growth ScoreC
    • Revenue YoY0.00%C
    • Net Profit YoY129.41%A
    • Total Assets YoY14.39%A
    • Net Assets YoY29.48%A
  • Cash ScoreC
    • Cash Flow Margin325.61%C
    • OCF YoY0.00%C
  • Operating ScoreC
    • Turnover0.47C
  • Debt ScoreA
    • Gearing Ratio20.02%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Black Diamond Therapeutics (NASDAQ:BDTX) Stock Rating Lowered by Guggenheim

    Guggenheim downgraded Black Diamond Therapeutics (NASDAQ:BDTX) from a "buy" rating to a "neutral" rating. Other analysts have mixed ratings, with some downgrading and others maintaining "buy" ratings. The stock's price target has been adjusted by various analysts, and the company's shares recently traded at $2.62. Institutional investors have shown interest in the company. Black Diamond Therapeutics focuses on developing therapies for genetically defined tumors.

    Market Beat·
    US
    BDTX
    +0.74%
    Market Beat·
    US
    BDTX
    +0.74%

    Promising Potential of Silevertinib in EGFR-Mutant NSCLC: Buy Rating Reiterated

    Analyst Robert Burns from H.C. Wainwright reiterated a Buy rating for Black Diamond Therapeutics, citing promising Phase 2 data for silevertinib in EGFR-mutant NSCLC. The drug showed a 60% response rate and strong CNS efficacy. Burns maintains a $10 price target, supported by a DCF valuation. Piper Sandler also initiated coverage with a Buy rating and a $9 target.

    Tip Ranks·
    US
    BDTX
    +0.74%
    Tip Ranks·
    US
    BDTX
    +0.74%

    Black Diamond Reports Promising Phase 2 Lung Cancer Data

    Black Diamond Therapeutics announced promising preliminary data from its Phase 2 trial of silevertinib for non-small cell lung cancer, showing a 60% objective response rate. The company plans a Phase 2 trial for glioblastoma in 2026. Despite financial challenges, the recent strategic partnership with Servier offers potential benefits. Analysts have mixed views on BDTX stock, with a recent Buy rating and a $9.00 price target, but also a high-risk assessment due to weak financials.

    Tip Ranks·
    US
    BDTX
    +0.74%
    Tip Ranks·
    US
    BDTX
    +0.74%

    BUZZ-Black Diamond rises as lung cancer drug meets main goal

    Shares of precision oncology firm Black Diamond Therapeuticsrise 3.8% to $3.58 premarketCo says its experimental cancer drug silevertinib met main goal with 60% tumor response and 86% brain response in 43 lung cancer patients with rare EGFR mutationsEGFR is a protein that helps cells grow; mutations can drive cancerSeparately, co says it plans to start a mid-stage trial of silevertinib in patients with glioblastoma, an aggressive form of brain cancer, in the first half of 2026Up to last close, stock up 61% YTD

    Reuters·
    US
    BDTX
    +0.74%
    Reuters·
    US
    BDTX
    +0.74%

    Black Diamond Therapeutics Announces Phase 2 Silevertinib Clinical Trial Results

    Black Diamond Therapeutics will host a webcast on December 3, 2025, to present Phase 2 clinical trial results of silevertinib, a fourth-generation EGFR inhibitor for EGFR-mutant NSCLC and glioblastoma. The webcast details are available on their website.

    Reuters·
    US
    BDTX
    +0.74%
    Reuters·
    US
    BDTX
    +0.74%
    © 2025 Longbridge｜Disclaimer